IMO, this submission will be the next announcement, along with OSA clinical trial results, I've always said, nothing is certain in the stock market but I can't see why CE Mark won't be approved given it uses the same algorithm (different data-set but the result were as good) and clinical process as paediatric one.
Ann: ResApp Receives CE Mark for ResAppDx-EU, page-574
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #